Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>Neoadjuvant chemotherapy (NAC) has been widely performed in the treatment of colorectal cancer liver metastasis (CRLM) patients, but the optimal timing of surgery after NAC is unclear. The aim of this study was to investigate the optimal timing of surgery.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>From December 2010 to May 2018, 101 consecutive patients who received NAC followed by liver resection for CRLM were included in this study. The main outcome parameters were pathological response, progression‐free survival (PFS), and overall survival (OS). The effect of time to surgery (TTS) on patient outcomes, defined as a high TTS and a low TTS according to an X‐tile analysis, was investigated. To adjust for potential selection bias, propensity score matching at 1:2 was performed with two high TTS patients matched to one low TTS patient. Kaplan‐Meier curves, logistic regression analyses, and Cox regression models were used for the data analysis.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>The optimal cut‐off value for the TTS was 5 weeks by X‐tile analysis. The patients in this study were divided into low (≤5 weeks, n = 27) and high (>5 weeks, n = 74) TTS groups. Patients with a high TTS were more likely to have an unfavorable pathological response (75.7% vs 48.1%, <i>P</i> = .008). In multivariate analysis, a low TTS significantly predicted a better pathological response (OR = 3.397, 95% CI: 1.116‐10.344, <i>P</i> = .031). Compared to patients with a high TTS, patients with a low TTS had significantly better PFS (<i>P </i><.001, mPFS: 16 months vs 7 months) and better OS (<i>P</i> = .037, mOS: not reached vs 36 months). Multivariate analysis revealed that a TTS > 5 weeks was an independent predictor of decreased PFS (HR = 2.041, 95% CI: 1.152‐3.616, <i>P</i> = .014) but not OS. After propensity matching, the patients with a low TTS had significantly better PFS (<i>P </i>< .001, mPFS: 18.2 months vs 10 months) and an equivalent OS (<i>P</i> = .115, mOS: not reached vs 41 months). Multivariate analysis revealed that a TTS > 5 weeks was an independent predictor of decreased PFS (HR = 3.031, 95% CI: 1.494‐6.149, <i>P</i> = .002) but not OS. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion</h3><p>The longer TTS after the completion of NAC may be disadvantageous for a favorable pathological response and long‐term PFS. These results should be validated prospectively in a randomized trial.</p></section>

Longer Time Interval from Neoadjuvant Chemoradiation to Surgery is Associated with Poor Survival for Patients Without Clinical Complete Response in Oesophageal Cancer

Effect of Interval Between Neoadjuvant Chemoradiotherapy and Surgery on Oncological Outcomes in Poor Responders with Locally Advanced Rectal Cancer: a Retrospective Cohort Study.

Neoadjuvant Chemotherapy Versus Surgery Alone For Locally Advanced Gastric Cancer: A Retrospective Comparative Study

FOLFOX Versus EOX As a Neoadjuvant Chemotherapy Regimen for Patients with Advanced Gastric Cancer

Does the time interval from neoadjuvant camrelizumab combined with chemotherapy to surgery affect outcomes for locally advanced esophageal squamous cell carcinoma?

Increasing the Interval Between Neoadjuvant Chemoradiotherapy and Surgery in Esophageal Cancer: A Meta-Analysis of Published Studies.

Impact of interval between neoadjuvant chemoradiotherapy and surgery in rectal cancer patients

Oesophagectomy following noncurative endoscopic resection for oesophageal carcinoma: does interval matter?

Impact of the interval between neoadjuvant immunotherapy and surgery on prognosis in esophageal squamous cell carcinoma (ESCC): a real-world study

The significance of time interval between perioperative SOX/XELOX chemotherapy and clinical decision model in gastric cancer

Concurrent neoadjuvant chemoradiotherapy could improve survival outcomes for patients with esophageal cancer: a meta-analysis based on random clinical trials

Timing of Adjuvant Chemoradiation in pT1-3N1-2 or pT4aN1 Esophageal Squamous Cell Carcinoma After R0 Esophagectomy

Optimal timing of surgery following neoadjuvant chemoradiotherapy in locally advanced rectal cancer

Improved Prognosis with Induction Chemotherapy in Pathological Complete Responders after Trimodality Treatment for Esophageal Squamous Cell Carcinoma: Hypothesis Generating for Adjuvant Treatment.

Timing After Neoadjuvant Therapy Predicts Mortality in Patients Undergoing Esophagectomy: a Propensity Score-Matched Analysis

Interval time between neoadjuvant chemotherapy and surgery in advanced gastric cancer doesn't affect outcome: A meta analysis

Optimal timing of surgery for gastric cancer after neoadjuvant chemotherapy: a systematic review and meta-analysis

Long-term Survival of Patients with Locally Advanced Esophageal Squamous Cell Carcinoma Receiving Esophagectomy Following Neoadjuvant Chemotherapy: a Cohort Study

Evaluation of response of esophageal cancer to neoadjuvant therapy and the choice of operation time after treatment

Optimal Timing to Surgery After Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer

From the completion of neoadjuvant chemotherapy to surgery for colorectal cancer liver metastasis: What is the optimal timing?